neuronata r (Corestem Inc)
86
Structured Review
Corestem Inc
neuronata r
Neuronata R, supplied by Corestem Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/neuronata-r/neuronata+r/pmc13176351-21-2-3
Average 86 stars, based on 1 article reviews
Neuronata R, supplied by Corestem Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/neuronata-r/neuronata+r/pmc13176351-21-2-3
Average 86 stars, based on 1 article reviews
neuronata r - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
In Vitro:Article Title: Mesenchymal and induced pluripotent stem cell–based therapeutics: a comparison Article Snippet: Article Title: Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options Article Snippet: Neuronata-R , Article Title: Stem cell therapies in the clinic Article Snippet: Article Title: Cellular expansion of MSCs : Shifting the regenerative potential Article Snippet: Article Title: Developing standards to support the clinical translation of stem cells. Article Snippet: The guidelines recommend that research related to human embryos (eg, preimplantation stages of human development, in vitro human embryo culture, derivation of TABLE 1 Representative approved stem cell products on the market Region Trade name Cell type Manufacturer Indications United States ALLOCORD HPC cord blood SSM Cardinal Glennon Children's Medical Center Hematopoietic and immunologic reconstitution United States Ducord HPC cord blood Duke University School of Medicine Hematopoietic and immunologic reconstitution United States Clevecord HPC cord blood Cleveland Cord Blood Center Hematopoietic and immunologic reconstitution United States Hemacord HPC cord blood New York Blood Center, Inc Hematopoietic and immunologic reconstitution Europe Alofisel Allogeneic MSC extracted from adipose tissue Takeda Complex anal fistulas in adults with Crohn's disease Europe Zynteglo Genetically modified autologous CD34+ cell enriched population that contains HSC Bluebird bio (Netherlands) B.V. Beta-thalassemia Europe Strimvelis Autologous CD34+ enriched cell fraction contains genetically modified CD34+ cells Orchard Therapeutics (Netherlands) BV Severe combined immunodeficiency Japan Temcell Allogeneic MSC from BM JCR Pharmaceuticals Co. Ltd Acute GVHD Japan Stemirac Autologous MSC from BM Nipro Corporation Spinal cord injury South Korea NeuroNATA-R Autologous MSC from Article Title: Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19 Article Snippet: In line with this, there has been global approval of several MSC-based therapies, including Temcell HS Inj (JCR Pharmaceuticals, approved in Japan, 2015) for GvHD; Cellgram-AMI (FCB-Pharmicell, approved in South Korea, 2011) for myocardial infarction; Prochymal/remestemcel-L (Osiris, approved in Canada and New Zealand, 2012) for GvHD; Cartistem (Medipost, approved in South Korea, 2012) for knee articular cartilage defect; Embryo Culture:Article Title: Mesenchymal and induced pluripotent stem cell–based therapeutics: a comparison Article Snippet: Article Title: Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options Article Snippet: Neuronata-R , Article Title: Stem cell therapies in the clinic Article Snippet: Article Title: Cellular expansion of MSCs : Shifting the regenerative potential Article Snippet: Article Title: Developing standards to support the clinical translation of stem cells. Article Snippet: The guidelines recommend that research related to human embryos (eg, preimplantation stages of human development, in vitro human embryo culture, derivation of TABLE 1 Representative approved stem cell products on the market Region Trade name Cell type Manufacturer Indications United States ALLOCORD HPC cord blood SSM Cardinal Glennon Children's Medical Center Hematopoietic and immunologic reconstitution United States Ducord HPC cord blood Duke University School of Medicine Hematopoietic and immunologic reconstitution United States Clevecord HPC cord blood Cleveland Cord Blood Center Hematopoietic and immunologic reconstitution United States Hemacord HPC cord blood New York Blood Center, Inc Hematopoietic and immunologic reconstitution Europe Alofisel Allogeneic MSC extracted from adipose tissue Takeda Complex anal fistulas in adults with Crohn's disease Europe Zynteglo Genetically modified autologous CD34+ cell enriched population that contains HSC Bluebird bio (Netherlands) B.V. Beta-thalassemia Europe Strimvelis Autologous CD34+ enriched cell fraction contains genetically modified CD34+ cells Orchard Therapeutics (Netherlands) BV Severe combined immunodeficiency Japan Temcell Allogeneic MSC from BM JCR Pharmaceuticals Co. Ltd Acute GVHD Japan Stemirac Autologous MSC from BM Nipro Corporation Spinal cord injury South Korea NeuroNATA-R Autologous MSC from Article Title: Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19 Article Snippet: In line with this, there has been global approval of several MSC-based therapies, including Temcell HS Inj (JCR Pharmaceuticals, approved in Japan, 2015) for GvHD; Cellgram-AMI (FCB-Pharmicell, approved in South Korea, 2011) for myocardial infarction; Prochymal/remestemcel-L (Osiris, approved in Canada and New Zealand, 2012) for GvHD; Cartistem (Medipost, approved in South Korea, 2012) for knee articular cartilage defect; Genetically Modified:Article Title: Mesenchymal and induced pluripotent stem cell–based therapeutics: a comparison Article Snippet: Article Title: Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options Article Snippet: Neuronata-R , Article Title: Stem cell therapies in the clinic Article Snippet: Article Title: Cellular expansion of MSCs : Shifting the regenerative potential Article Snippet: Article Title: Developing standards to support the clinical translation of stem cells. Article Snippet: The guidelines recommend that research related to human embryos (eg, preimplantation stages of human development, in vitro human embryo culture, derivation of TABLE 1 Representative approved stem cell products on the market Region Trade name Cell type Manufacturer Indications United States ALLOCORD HPC cord blood SSM Cardinal Glennon Children's Medical Center Hematopoietic and immunologic reconstitution United States Ducord HPC cord blood Duke University School of Medicine Hematopoietic and immunologic reconstitution United States Clevecord HPC cord blood Cleveland Cord Blood Center Hematopoietic and immunologic reconstitution United States Hemacord HPC cord blood New York Blood Center, Inc Hematopoietic and immunologic reconstitution Europe Alofisel Allogeneic MSC extracted from adipose tissue Takeda Complex anal fistulas in adults with Crohn's disease Europe Zynteglo Genetically modified autologous CD34+ cell enriched population that contains HSC Bluebird bio (Netherlands) B.V. Beta-thalassemia Europe Strimvelis Autologous CD34+ enriched cell fraction contains genetically modified CD34+ cells Orchard Therapeutics (Netherlands) BV Severe combined immunodeficiency Japan Temcell Allogeneic MSC from BM JCR Pharmaceuticals Co. Ltd Acute GVHD Japan Stemirac Autologous MSC from BM Nipro Corporation Spinal cord injury South Korea NeuroNATA-R Autologous MSC from Article Title: Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19 Article Snippet: In line with this, there has been global approval of several MSC-based therapies, including Temcell HS Inj (JCR Pharmaceuticals, approved in Japan, 2015) for GvHD; Cellgram-AMI (FCB-Pharmicell, approved in South Korea, 2011) for myocardial infarction; Prochymal/remestemcel-L (Osiris, approved in Canada and New Zealand, 2012) for GvHD; Cartistem (Medipost, approved in South Korea, 2012) for knee articular cartilage defect; Derivative Assay:Article Title: Mesenchymal and induced pluripotent stem cell–based therapeutics: a comparison Article Snippet: Article Title: Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options Article Snippet: Neuronata-R , Article Title: Stem cell therapies in the clinic Article Snippet: Article Title: Cellular expansion of MSCs : Shifting the regenerative potential Article Snippet: Article Title: Developing standards to support the clinical translation of stem cells. Article Snippet: The guidelines recommend that research related to human embryos (eg, preimplantation stages of human development, in vitro human embryo culture, derivation of TABLE 1 Representative approved stem cell products on the market Region Trade name Cell type Manufacturer Indications United States ALLOCORD HPC cord blood SSM Cardinal Glennon Children's Medical Center Hematopoietic and immunologic reconstitution United States Ducord HPC cord blood Duke University School of Medicine Hematopoietic and immunologic reconstitution United States Clevecord HPC cord blood Cleveland Cord Blood Center Hematopoietic and immunologic reconstitution United States Hemacord HPC cord blood New York Blood Center, Inc Hematopoietic and immunologic reconstitution Europe Alofisel Allogeneic MSC extracted from adipose tissue Takeda Complex anal fistulas in adults with Crohn's disease Europe Zynteglo Genetically modified autologous CD34+ cell enriched population that contains HSC Bluebird bio (Netherlands) B.V. Beta-thalassemia Europe Strimvelis Autologous CD34+ enriched cell fraction contains genetically modified CD34+ cells Orchard Therapeutics (Netherlands) BV Severe combined immunodeficiency Japan Temcell Allogeneic MSC from BM JCR Pharmaceuticals Co. Ltd Acute GVHD Japan Stemirac Autologous MSC from BM Nipro Corporation Spinal cord injury South Korea NeuroNATA-R Autologous MSC from Article Title: Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19 Article Snippet: In line with this, there has been global approval of several MSC-based therapies, including Temcell HS Inj (JCR Pharmaceuticals, approved in Japan, 2015) for GvHD; Cellgram-AMI (FCB-Pharmicell, approved in South Korea, 2011) for myocardial infarction; Prochymal/remestemcel-L (Osiris, approved in Canada and New Zealand, 2012) for GvHD; Cartistem (Medipost, approved in South Korea, 2012) for knee articular cartilage defect; |
